OptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have earned an average rating of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.06.

A number of research analysts recently commented on OPRX shares. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research note on Wednesday, March 12th. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price target on shares of OptimizeRx in a research note on Thursday, February 6th. Stephens started coverage on shares of OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target on the stock. Finally, Lake Street Capital reiterated a “buy” rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Delta Investment Management LLC acquired a new position in shares of OptimizeRx during the 4th quarter worth approximately $146,000. Squarepoint Ops LLC grew its position in shares of OptimizeRx by 298.8% during the 4th quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock worth $203,000 after purchasing an additional 31,252 shares in the last quarter. Tang Capital Management LLC bought a new stake in shares of OptimizeRx during the 4th quarter worth approximately $1,075,000. Graham Capital Management L.P. bought a new stake in shares of OptimizeRx during the 4th quarter worth approximately $81,000. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of OptimizeRx by 12.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company’s stock worth $1,437,000 after acquiring an additional 32,062 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Stock Up 9.1 %

OptimizeRx stock opened at $9.02 on Wednesday. The firm has a market capitalization of $166.16 million, a PE ratio of -6.78 and a beta of 1.31. The company’s 50-day moving average is $5.64 and its 200-day moving average is $5.90. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $14.13. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.